Navigation Links
Dialysis Corporation of America Announces Establishment of Clinical Grant Agreement with the University of Cincinnati, College of Medicine
Date:4/8/2009

LINTHICUM, Md., April 8 /PRNewswire-FirstCall/ -- Dialysis Corporation of America (Nasdaq: DCAI) announced today that it has entered into a grant agreement with the University of Cincinnati, College of Medicine.

The grant, which will total $265,000 each year, for the next three years, will be used solely to support and conduct basic and clinical research relating to kidney disease. This multi-year agreement gives Dialysis Corporation of America a platform from which to support consistent education and innovation in the areas surrounding kidney disease.

"DCA is dedicated to the advancement of kidney disease research, education and patient care," stated company President and CEO, Stephen Everett. "Formalizing this relationship with the University of Cincinnati allows Dialysis Corporation of America to support kidney disease research and education in a comprehensive way while working with an organization dedicated to its mission, independence, and integrity. University of Cincinnati's history of research and education makes this an excellent choice."

Under the agreement Dialysis Corporation of America will provide the University with the amounts due under the grant at the end of the first quarter of each of the three years of the agreement. The initial $265,000 grant amount was provided to the University on March 31st of this year.

Dialysis Corporation of America owns and operates freestanding kidney hemodialysis centers located in Georgia, Maryland, New Jersey, Ohio, Pennsylvania, South Carolina, and Virginia, and provides in-hospital dialysis services on a contract basis to certain hospitals located in those states. The company provides patients with their choice of a full range of quality in-center, acute or at-home hemodialysis services.

This release contains forward-looking statements that are subject to risks and uncertainties that could affect the business and prospects of the company and cause actual results and plans to differ materially from those anticipated. Those factors include, but are not limited to, increases in interest rates, the possible need for and availability of additional financing, the company's satisfying the covenants and conditions of its credit facility, certain delays beyond the company's control with respect to future business events, the highly competitive environment in the establishment and operation of dialysis centers, the ability to develop or acquire additional dialysis facilities, whether patient bases of the company's dialysis facilities can mature to provide profitability, the extensive regulation of dialysis operations, government rate determination for Medicare reimbursement, pricing pressure from private payors, and other risks detailed in the company's filings with the SEC, particularly as described in the company's annual report on Form 10-K for the fiscal year ended December 31, 2008. The historical results contained in this press release are not necessarily indicative of future performance of the company.

Other Dialysis Corporation of America press releases, corporate profile, corporate governance materials, quarterly and current reports, and other filings with the Securities and Exchange Commission are available on Dialysis Corporation of America's internet home page: http://www.dialysiscorporation.com.


'/>"/>
SOURCE Dialysis Corporation of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DaVitas IMPACT Program Reduces Mortality for New Dialysis Patients
2. Anti-microbial catheter to cut infection risk for dialysis patients
3. Dialysis Via Fistulas May Help Young or Old
4. NxStage Reports Sustained Reduction in Clinical Depressive Symptoms for Daily Home Hemodialysis Patients After One Year
5. Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results
6. Satellite Healthcare Researchers to Present at 29th Annual Dialysis Conference
7. Lowering BP in Dialysis Cases Cuts Heart Risks
8. Preparing for the Next Disaster: Dialysis Community Briefs Hill About Emergency Response
9. High-flux hemodialysis prolongs survival in many patients with CKD
10. Dialysis Corporation of America Announces Fiscal Year 2008 Earnings Release Date
11. B. Braun Wins Premier Contract for Full Line of Dialysis Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Beginning in 2017, Ridgecrest Herbals will be phasing ... the popular ClearLungs Extra Strength formula. To ensure that the effectiveness of Clear Lungs ... ways:, , Removal of the homeopathic element , ...
(Date:4/28/2017)... New York, NY (PRWEB) , ... April 28, ... ... Shiel Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast ... indicates recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
(Date:4/28/2017)... ... ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical organization GenCure, ... at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord blood donations ... , “Women’s Hospital at Renaissance has been a collection partner for the TCBB since ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to accept that hearing aids ... doesn’t have the stigma it had when great-grandpa wore his hearing aids years ago,” ... a NALA North American Speaker Series (NASS) segment. “He probably wore an ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
(Date:4/19/2017)... , April 19, 2017 The Global ... Forecast to 2022 report has covered and analysed the potential ... information on market size, shares and growth factors. The report ... challenges and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major ...
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
Breaking Medicine Technology: